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Abstract
Background: Serological tests can be important tools to assist in the diagnosis of leprosy and can contribute to an
earlier diagnosis. The aim of this study was to evaluate the antibody responses against phenolic glycolipid-1 (PGL-1),
natural disaccharide linked to human serum albumin via an octyl (NDO-HSA), Leprosy IDRI Diagnostic-1 (LID-1) and
natural disaccharide octyl - Leprosy IDRI Diagnostic-1 (NDO-LID) in leprosy patients, household contacts of patients and
the general population.
Methods: Enzyme-linked immunosorbent assays were used to analyze the antigen-specific antibody responsesof 94
leprosy cases, 104 household contacts of cases and 2.494 individuals from the general population.
Results: A positive correlation was observed for the antibody responses to all antigens studied. A higher proportion of
seropositivity for all antigens, along with stronger magnitude of response, was observed in multibacillary (MB) leprosy
patients and household contacts of MB leprosy patients compared with the levels observed in paucibacillary (PB)
leprosy patients and household contacts of PB leprosy patients. A substantial and significant positive correlation was
found between seropositivity and the bacterial index for the leprosy patients. Anti-PGL-1 tests were more frequently
positive than anti-NDO-HSA tests among patients with all clinical forms of leprosy and among the group of household
contacts. The LID-1 and NDO-LID antigens showed a greater capacity to identify household contacts and individuals
from the general population infected with M. leprae.
Conclusions: Tests that measure the antibody responses against LID-1, NDO-LID, NDO-HSA and PGL-1 were effective
tools for the detection of patients with MB leprosy. Our data indicate that the anti-LID-1 and anti-NDO-LID responses
were more effective than an anti-NDO-HSA response for the identification of individuals with subclinical infection.
Background
Leprosy presents across a wide range of symptoms de-
fined into 5–6 categories within the Ridley-Jopling scale,
although for treatment purposes these are simplified/
consolidated to either multi- or paucibacillary (MB and
PB, respectively). The diagnosis of leprosy is not simple
and, not surprisingly, many professionals have neither
the experience to recognize the various signs and symp-
toms of the disease nor the ability to differentiate them
from other diseases [1]. Thus, leprosy patients often re-
ceive incorrect diagnoses and appropriate treatment is
delayed.
Antibody responses to specific M. leprae antigens can
be evaluated by several tests. Among these are serologic
tests that measure the levels of immunoglobulin M
(IgM) against phenolic glycolipid-1 (PGL-1) (which may
be detected by either native (anti-PGL-1) [2] or the syn-
thetic mimetope natural disaccharide, typically linked to
human serum albumin via an octyl (NDO-HSA) [3]) IgG
against leprosy IDRI diagnostic 1 (LID-1) [4, 5] or both
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IgM and IgG against natural disaccharide octyl - leprosy
IDRI diagnostic 1 (NDO-LID) [1]. The titers of anti-
bodies against PGL-1, LID-1 and NDO-LID vary with
clinical presentation, being highest in the lepromatous -
lepromatous (LL) clinical form and lowest, or absent, in
the tuberculoid - tuberculoid (TT) form. The antibody
titers generally increase as the disease progresses across
the spectrum from the TT to the LL form. The bacterial
index (BI) similarly varies and is positively correlated
with antibody titers [1, 5, 6].
Individuals living in leprosy endemic areas, which are
typically impoverished and have high population dens-
ities, are commonly infected with M. leprae [7]. Thus,
the possibility that asymptomatically infected individuals
may be involved in the M. leprae transmission chain
should not be overlooked [8]. Subclinical M. leprae in-
fection in endemic populations is traditionally assessed
using either enzyme-linked immunosorbent assays (ELISA)
or lateral flow point-of-care (POC) tests to detect specific
antibodies [8, 9]. When used in this way these assays may
enable earlier identification and treatment of patients, and
thus contribute to both the prevention of physical disabil-
ities and the reduced transmission of M. leprae [4].
It has been demonstrated in various settings that
household contacts of untreated MB patients experience
greater exposure to M. leprae than the general popula-
tion (GPop) [6]. Anti-PGL-1 seropositivity in household
contacts of leprosy patients has been associated with an
increased risk of developing disease [9]. It is important,
however, to consider that individuals living in highly en-
demic regions may be routinely exposed to M. leprae
even if they do not live with a recognized patient. It
therefore becomes pertinent to understand the perform-
ance of tests involving the PGL-1, LID-1, NDO-LID and
NDO-HSA antigens in different contexts and groups
within the population. The aim of this study was to
evaluate serum antibody responses against PGL-1,
NDO-HSA, LID-1 and NDO-LID in patients diagnosed
with leprosy, in household contacts of leprosy patients
and among the general population of a leprosy endemic
region municipalities with varying leprosy detection rates.
Methods
Patient and contact samples
Untreated patients (n = 94) and household contacts (n = 104)
were recruited at the National Reference Centre for Sanitary
Dermatology and Leprosy (CREDESH), Uberlandia, Minas
Gerais, Brazil, a public health care facility in an en-
demic region where routine prevention, including Ba-
cillus Calmette–Guérin (BCG) vaccination, household
contact monitoring, early case detection, and treatment
are available and under constant supervision. The
Uberlândia municipality had detection rate of 10.81/
100.000 inhabitants in 2012 [10].
Leprosy patients were diagnosed after thorough
dermato-neurological and laboratory examinations, and
classified according Ridley-Jopling five-group system of
clinical manifestations into: tuberculoid (TT), borderline
tuberculoid (BT), mid-borderline (BB), borderline lep-
romatous (BL) or lepromatous (LL) [11]. For treatment
purposes patients were also stratified into paucibacillary
(PB), with up to five skin lesions and a negative bacillo-
scopy, or MB, with more than five lesions and/or posi-
tive bacilloscopy in accordance with the World Health
Organization operational classification [12].
Household contacts (HHC) who resided with leprosy
patients, or had resided with leprosy patients in the five
years prior to diagnosis, were examined for signs or
symptoms that were suggestive of leprosy by physicians
with specialized leprosy training. Most HHC were rela-
tives of their index case (spouse, parent or sibling). HHC
were stratified according to the operational and clinical
classifications of their index case.
Samples from the general population
Individuals from the general population (GPop; n =
2.494) were selected randomly from seven municipal-
ities in the microregion of Almenara, Minas Gerais,
Brazil [13], which had a mean detection rate of 31.32/
100.000 inhabitants in 2012 [10]. Finger-prick blood
spots were collected on Whatman 3 MM paper (Whatman,
Maidstone, UK) and stored at 4 °C until serum was eluted
by adding 1 % bovine serum albumin in 1X phosphate buff-
ered saline. Based on estimates of the volume of whole
blood in a 2.5 mm filter paper disc, the final dilution of the
eluted serum was 1:100 [14, 15].
Antibody detection
Antigen-specific IgM and IgG antibodies were measured
by indirect enzyme-linked immunosorbent assays (ELISA)
as previously described [3]. Briefly, the four antigens
(PGL-1, NDO-HSA, LID-1 and NDO-LID) were used to
coat 96-well microtiter plates (LABWARE Manufacture
CO, People’s Republic of China); 1 μg/mL of LID-1 or
0.2 μg/mL of NDO-HSA, NDO-LID or PGL-1 was added
per well in 100 μL of 0.1 M sodium carbonate/bicarbonate
buffer, pH 9.6, and incubated at 4 °C overnight. The assay
was performed using serum samples at a dilution of 1:300
and whole blood samples at a dilution of 1:100 [14, 15].
After blocking for 1 h at 37 °C, detection antibodies were
similarly incubated for 1 h at 37 °C, after which four
washes were performed. The wells were then treated with
ortho-phenylenediamine (OPD) substrate, and the absorb-
ance at 492 nm was obtained using a spectrophotometer
plate reader (Molecular Devices, Sunnyvale, CA). To
minimize inter- and intra-test errors, an ELISA index (EI)
was calculated as follows: the EI equals the optical density
(OD) of the sample divided by the OD of the cut-off [5].
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The cut-off was calculated as an average of three controls
negative (individuals living in low endemic areas leprosy
and which showed result of the ML Flow test negative) plus
three times the standard deviation, such that samples with
EI values of 1.1 or above were considered to be positive.
Statistical analysis
Graphs and mean values were generated using GraphPad
Prism version 5 (GraphPad Software Inc., La Jolla, CA,
USA), and statistical analysis was performed using Stat-
istical Package for the Social Sciences (SPSS) version 18
(SPSS Inc., Chicago, IL, USA). Statistical significance
was assessed using nonparametric methods, with the
Kruskal-Wallis one-way (H) analysis of variance used to
make comparisons among multiple groups and the
Mann–Whitney U test with Bonferroni correction used
to make comparisons between two groups. Spearman’s
coefficient (rho) was used to test the strengths of corre-
lations. Results were considered statistically significant
when p-values ≤0.05 were obtained or when p-values
≤0.0167 using the Mann–Whitney U test. The concord-
ance among the four antigens was calculated using the
Kappa coefficient. The NDO-HSA antigen was selected
as the reference antigen because it was tested in three
groups (patients, HHC and GPop) and because it is one
of the most common antigens used in tests for M.
leprae. Kappa values and their interpretation varied as
follows: <0, no agreement; 0–0.20, poor agreement; 0.21-
0.40, fair agreement; 0.41-0.60, moderate agreement;
0.61-0.80, substantial agreement; and 0.81-1.00, almost
perfect agreement [16].
Ethics statement
This study conforms to the Declaration of Helsinki and
was reviewed and approved by Research Ethic Committee
(CEP) of the Federal University of Uberlandia, Protocol
Number CEP/UFU 138/08, and the Research Ethic
Committee (COEP) of the Federal University of Minas
Gerais, Protocol Number ETIC 158/09. All participants
signed an informed consent form and authorized the
collection of the samples. The informed consent form
for children under 18 years of age was signed by either
a parent or a legal guardian.
Results
Antibody responses among leprosy patients
We determined the presence of antigen-specific anti-
bodies in the serum samples from various groups. In the
group of patients, as anticipated the seropositivity of
antibodies against LID-1, NDO-LID, NDO-HSA and
PGL-1 were highest in MB patients and lowest in PB pa-
tients (BT and TT forms). Antibodies against NDO-LID
(28.3 %) and PGL-1 (33.3 %) were, however, better able
to detect PB patients than both LID-1 (10.5 %) and
NDO-HSA (23.3 %) (Table 1). Further analyses within
the context of the Ridley-Jopling scale demonstrated that
100 % (n = 14) LL patients were seropositive for anti-
NDO-LID and anti-PGL-1, while 85.7 % (n = 12) and
92.9 % (n = 13) were seropositive for anti-LID-1 and
anti-NDO-HSA, respectively. Notably, the seropositivity
rates for antibodies against the 4 antigens evauated were
significantly different between the TT and LL groups
(Fig. 1). The NDO-LID antigen had a higher seropositiv-
ity rate than LID-1 and NDO-HSA in the BT group. In
the BL group the LID-1 antigen had a higher seroposi-
tivity rate than NDO-LID, and in LL group PGL-1 was
observed to have a higher seropositivity than NDO-LID
(Fig. 2). In addition, a positive correlation was observed
for the bacterial indices (BI) and the antibody titers
against LID-1 (rho = 0.81), NDO-LID (rho = 0.67), NDO-
HSA (rho = 0.60) and PGL-1 (rho = 0.61) (all p < 0.0001).
Thus, our data indicate that EI increase with BI and
across the disease spectrum.
Responses of household contacts (HHC) and the general
population (GPop)
It is documented that HHC are at higher risk of M.
leprae infection and development of disease than the
general population. We therefore analyzed the antigen-
specific antibody responses of HHC and a random selection
of residents (GPop) within the leprosy endemic region of
Minais Gerais. The seropositivity rate was higher among
the HHC of MB patients than those of PB patients,
supporting the hypothesis that HHC of MB patients are
exposed and more likely to be infected with M. leprae
(Table 1). Positive responses were also detected among the
GPop. Together, these data suggest a large proportion
may be harboring M. leprae without any clinical symp-
toms of disease.
Relationship of responses
Significant differences were observed between the EI for
antibodies to NDO-LID and NDO-HSA in the patient,
HHC and GPop. It is noteworthy that for NDO-LID and
Table 1 Proportion of seropositivity for antibodies against LID-1,
NDO-LID, NDO-HSA and PGL-1 according to groups of individuals
No. (%) positivea
No. of samples LID-1 NDO-LID NDO-HSA PGL-1
Patients MB 43 34(89.5) 38(71.7) 33(76.7) 38(66.7)
PB 51 4(10.5) 15(28.3) 10(23.3) 19(33.3)
HHC MBb 81 35(43.2) 31(38.3) 10(12.3) 14(17.3)
PBc 23 6(26.1) 6(26.1) 0(0.0) 1(4.3)
GPop 2494 74(21.9) 995(41.2) 191(7.9) -
aTest were considered positive when a distinct band was observed (scored as
EI of 1.1 or greater)
bHHC of patients classified as MB
cHHC of patients classified as PB
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NDO-HSA the mean EI of GPop was higher than that of
HHC. A significant difference was also observed be-
tween the patient group and HHC for PGL-1 (Fig. 3).
The concordance between the anti-NDO-HSA and anti-
LID-1 (k = 0.63), anti-PGL-1 (k = 0.62) and anti-NDO-LID
(k = 0.79) was substantial and significant in the patient
group (all p < 0.0001). In GPop the agreement was poor,
while in HHC fair agreement was observed between the
result of antibodies against NDO-HSA and NDO-LID
(k = 0.32; p < 0.0001).
Using the Spearman test, a significant positive correl-
ation was identified between the different antigens tested
in GPop as well as in the patients. In HHC, no signifi-
cant correlation was identified for any combination with
the PGL-1 antigen (Table 2). We observed that the cor-
relation was higher in the group of patients.
Discussion
We examined the presence of antibodies against particu-
lar M. leprae antigens among various groups living in a
leprosy endemic region. Consistent with previous obser-
vations [1, 5, 6], positive correlations with patient BI
were observed for all of the antigens. Moreover, higher
seropositivity was observed for anti-LID-1, anti-NDO-
LID, anti-NDO-HSA and anti-PGL-1 in MB patients
(BL, LL and some BB patients) and in HHC of MB pa-
tients than in PB patients and their HHC. A large pro-
portion of the general population were also found to be
Fig. 1 Antigen-specific responses of leprosy patients, stratified by antigen. Sera from fully characterized leprosy patients were analyzed for
antibodies against a. LID-1 (IgG); b. NDO-LID (IgG and IgM); c. NDO-HSA (IgM) and d. PGL-I (IgM). Each point represents the EI of an individual
serum sample. The mean EI is represented by the horizontal line. The traced horizontal line is threshold for determining a positive result (EI = 1.1).
The number above each data set is the percentage of positive results, and the number below each data set represents the total number of
participants in each group
Fabri et al. BMC Infectious Diseases  (2015) 15:218 Page 4 of 9
seropositive. Together, our data suggest that a relatively
large proportion of the population may harbor M. leprae
infection.
In agreement our findings, an earlier comparison of
antibodies against either native PGL-1 or semisynthetic
NDO-HSA demonstrated significant agreement between
these assays [3]. Our evaluations expand this observation
and identify significant agreement across patient groups
for seropositivity against the LID-1, NDO-LID, NDO-
HSA and PGL-1. In contrast, such agreements were not
observed in HHC or within the general population. We
speculate that agreement in the antigen-specific antibody
responses is observed in MB patients because they
present with a high bacterial load and a more developed
and defined humoral response. Of note, antibody re-
sponses to M. leprae appear to develop heterogeneously
even in the controlled setting of experimental infection
of armadillos [17], and thus, antigen-specific responses
may develop at differing rates and be variable in infected
individuals who have not yet exhibited signs of disease.
Some of the assays described here, for example ELISA
detecting antibodies against the NDO-LID conjugate,
appear to be more sensitive than others in the general
population. The positive correlation observed for anti-
bodies to the LID-1, NDO-HSA and NDO-LID antigens
in patients, HHC and the general population infer that
although the tests do not show perfect agreement, the
value of the EI of a particular individual has a unidirec-
tional trend.
The NDO-LID conjugate has previously demonstrated
a greater capacity to identify patients with MB leprosy
than the either of the NDO-HSA and LID-1 antigens
alone [1]. Although serological tests appear to have a
limited ability to aid the diagnosis of PB patients, our
data also identified that a greater number of PB patients
were seropositive for antibodies against NDO-LID than
against either NDO-HSA or LID-1 alone, as has been
reported previously [1, 6, 18]. This was especially true
for patients categorized into the BT group, an effect
similarly observed in a study of rapid diagnostic tests
(NDO-LID, Orange Life®) [6]. These findings suggest
the possibility of using NDO-LID-based tests within
leprosy control programs to identify patients early in
the clinical spectrum of leprosy and to identify PB
patients.
Our data indicate that tests detecting antibodies to
PGL-I and/or LID-1 represent effective tools for the de-
tection of MB patients. Among all clinical forms of lep-
rosy and among HHC the use of native PGL-1 resulted
in a higher positivity rate than the synthetic mimetic of
Fig. 2 Antigen-specific responses of leprosy patients, stratified by Ridley-Jopling classification. Sera from leprosy patients characterized as a. TT;
b. BT; c. BB; d. BL or e. LL were analyzed for antibodies against LID-1 (IgG), NDO-LID (IgG and IgM), NDO-HSA and PGL-I (IgM). Each point
represents the EI of an individual serum sample. The mean EI is represented by the horizontal line. The traced horizontal line is threshold for
determining a positive result (EI = 1.1)
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PGL-1 (NDO, conjugated to the inert carrier protein
HSA). This result is in agreement with the literature, as
a study comparing ELISA involving PGL-1 or NDO-
HSA with the ML Flow rapid test indicated that native
PGL-1 ELISA resulted in greater sensitivity and accuracy
than either the NDO-HSA ELISA or ML Flow tests [3].
In our comparison of leprosy patients a higher mean EI
was observed for PGL-1 than NDO-LID and LID-1.
However, the need to extract native PGL-1 from the or-
gans of M. leprae-infected armadillos is limiting and the
sustainable use of synthetic NDO is preferred [19]. Rela-
tive to the NDO-HSA antigen, the NDO-LID conjugate
demonstrated a greater potential to identify infected
HHC and individuals from the general population who
were infected with M. leprae. These tools could also be
used to aid clinicians lacking expertize in leprosy
Fig. 3 Antigen-specific responses among the broader population. Sera from multiple groups were analyzed for antibodies against a. LID-1 (IgG);
b. NDO-LID (IgG and IgM); c. NDO-HSA (IgM) and d. PGL-I (IgM). Each point represents the EI of an individual serum sample, with the total
number of participants in each group noted below. The mean EI is represented by the horizontal line. The traced horizontal line is threshold for
determining a positive result (EI = 1.1). a: IgG against LID-1: Patients versus HHCs versus Gpop, difference not significant (H = 0.57; p = 0.753). b: IgG
and IgM against NDOLID: Patients versus HHCs versus Gpop (H = 31.37). Mann–Whitney U test with Bonferroni correction: Patients versus HHCs
(p < 0.0001); Patients versus GPop (p < 0.0001); HHCs versus GPop * mean EI of the GPop group was greater than the mean EI of the HHCs group
(p < 0.0001). c: IgM against NDOHSA: Patients versus HHCs versus GPop (H = 50.66). Mann–Whitney U test with Bonferroni correction: Patients versus
HHCs (p < 0.0001); Patients versus GPop (p = 0.013); HHCs versus GPop * mean EI of the EC group was greater than the mean EI of the HHCs group
(p < 0.0001). d: IgM against PGL-1: Patients versus HHCs (U = 1769; p < 0.0001)
Fabri et al. BMC Infectious Diseases  (2015) 15:218 Page 6 of 9
diagnosis in general health care services to identify indi-
viduals at high risk of developing leprosy.
There is an epidemiological need for applicable diag-
nostic tools to detect asymptomatic individuals infected
with M. leprae and those patients with early manifesta-
tions of leprosy. The periodic evaluation of seropreva-
lence rates in leprosy endemic areas may also be a useful
measure of M. leprae transmission [20]. We expected to
observe a greater positivity among HHC than in the gen-
eral population because HHC are thought to be regularly
exposed to M. leprae up until the patient is undergoing
treatment [21]. On the contrary, however, we observed a
higher rate of anti-NDO-LID and anti-NDO-HSA posi-
tivity in the general population than HHC, although a
limitation of the study design was that the general popu-
lation was from a different region than the patients and
HHC. The higher endemicity rate in the region from
which the general population samples were collected
probably contributed to the higher seroposivity rate and
leads us to suggest that that population is regularly being
exposed to M. leprae and suggests that the hidden
prevalence of leprosy may be quite high [22].
Serological tests involving synthetic PGL-1 antigen are
used in some regions to identify individuals, especially
HHC, infected with M. leprae [8, 9]. Our findings sup-
port the use of tests evaluating the anti-NDO-LID re-
sponse, especially among HHC and in the general
population of areas of high endemicity for leprosy. The
application of anti-NDO-LID tests in the general popu-
lation could assist leprosy control programs by allowing
simple identification of a larger number of individuals
infected with M. leprae and consequently those that
have high risk of developing leprosy. Of particular rele-
vance for the practicalities of large scale surveillance
programs, our analysis of the general population exam-
ined whole blood collected on filter paper. A previous
study demonstrated that samples stored in filter paper
allowed for the recovery of antibody levels similar to
those in serum samples [14] and that there is a close
correlation between studies using venipuncture samples
captured on filter paper [23, 24]. It is believed, therefore,
that analysis of samples collected on filter paper was not
a detrimental or limiting factor for our study.
The high positivity in the general population for anti-
bodies to all of the studied antigens should raise concern
because multiple reports suggest that individuals with
subclinical M. leprae infection may be a potential trans-
mission source for the infection of additional people [8].
As suggested by others, we support the georeferencing
of patients and M. leprae-infected individuals to identify
population clusters that might benefit from greater
leprosy-specific vigilance by general health services. Fur-
thermore, the quantitative measurement of antibodies
against these antigens would appear beneficial in the se-
lection of seropositive individuals for clinical examin-
ation and the earlier detection of leprosy cases.
Conclusions
We observed high rates of seropositivity for antibodies
against LID-1, NDO-LID, NDO-HSA and PGL-1 anti-
gens among various groups within the population. High
rates were observed for all antigens in MB patients and
HHC of MB patients, and a positive correlation was ob-
served between serology and BI; marked, significant
agreement was found between these measures in leprosy
patients, in particular, but a positive correlation was also
observed in the general population.
The LID-1 and NDO-LID antigens showed a greater
capacity to identify HHC and individuals of the general
population infected with M. leprae. PGL-1 resulted in a
higher degree of positivity than NDO-HSA for all clin-
ical forms of leprosy and for HHC.
We suggest that NDO-LID represents an important
antigen for the surveillance of HHC and of the general
population. Our data provide evidence that all of the an-
tigens tested are relevant tools to support the oper-
ational classification of leprosy and can also be used to
identify individuals infected with M. leprae.
Table 2 Results of the Spearman test in different groups of individuals according to antigen
GPop HHC Patients
Antigens rho p-value rho p-value rho p-value
LID-1 and NDO-LID 0.635 <0.0001 0.345 0.0003 0.816 <0.0001
LID-1 and NDO-HSA 0.506 <0.0001 0.434 <0.0001 0.726 <0.0001
NDO-LID and NDO-HSA 0.323 <0.0001 0.864 <0.0001 0.875 <0.0001
PGL-1 and NDO-LID - - 0.150 0.129 0.727 <0.0001
PGL-1 and NDO-HSA - - 0.134 0.097 0.718 <0.0001
LID-1 and PGL-1 - - −0.122 0.219 0.646 <0.0001
rho: Spearman coefficient
LID-1: Leprosy IDRI diagnostic 1
NDO-LID: Natural disaccharide octyl - leprosy IDRI diagnostic 1
NDO-HSA: Natural disaccharide linked to human serum albumin via an octyl
PGL-1: Phenolic glycolipid-1
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The results of this study indicate the need for greater
vigilance in the health services in regions with high lep-
rosy endemicity because many cases may currently be
undiagnosed. These undiagnosed cases likely contribute
to the continued transmission of M. leprae and mainten-
ance of leprosy as an ongoing health concern.
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